Lista de obras - Tanja Trarbach - Dominio Público Uruguay

A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer

artículo científico publicado en 2007

A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).

artículo científico publicado en 2016

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).

artículo científico publicado en 2017

Adjuvant therapy in colon cancer

artículo científico publicado en 2010

Adjuvant therapy of colon carcinoma

artículo científico publicado en 2008

An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer

artículo científico publicado en 2011

Cancer patients and the Internet: a survey of the 'Quality of Life' Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie

artículo científico publicado en 2011

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

artículo científico publicado en 2010

Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS)

scientific article published on 18 March 2019

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

artículo científico publicado en 2014

Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.

artículo científico publicado en 2006

Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group.

artículo científico publicado en 2008

Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

artículo científico publicado en 2010

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

artículo científico publicado en 2014

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.

artículo científico publicado en 2010

Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.

artículo científico publicado en 2018

Long-term survival after "liver first" approach for locally advanced rectal cancer and synchronous liver metastases

scientific article published on 16 December 2010

Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy

artículo científico publicado en 2017

Novel prognostic scoring system after surgery for Klatskin tumor.

artículo científico publicado en 2013

Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients

artículo científico publicado en 2009

Optimized retroviral transduction protocol for human progenitor cells utilizing fibronectin fragments.

artículo científico publicado en 2000

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours

scientific article published on 12 October 2011

Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas

artículo científico publicado en 2012

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

artículo científico publicado en 2004

Prognostic impact of intrahepatic lymphatic and microvascular involvement in cases of colorectal liver metastases

artículo científico publicado en 2009

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction.

artículo científico publicado en 2013

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial

artículo científico publicado en 2016

Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project.

artículo científico publicado en 2019

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

scientific article published on 04 April 2011

Rectal cancer and synchronous metastases: resection of primary tumor or not?

artículo científico publicado en 2009

Safety distance in the resection of colorectal lung metastases: a prospective evaluation of satellite tumor cells with immunohistochemistry.

artículo científico publicado en 2010

Surgical treatment of Klatskin tumor: liver resection versus transplantation.

artículo científico publicado en 2010

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).

artículo científico publicado en 2014

Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference?

artículo científico publicado en 2008

Ten-year survival of esophageal cancer after an en-bloc esophagectomy.

artículo científico publicado en 2011

Tumor markers as a diagnostic key for hilar Cholangiocarcinoma ⬇️

artículo científico publicado el 20 de agosto de 2010

[Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology].

artículo científico publicado en 2010

[Laparoscopic surgery and adjuvant therapy for colon cancer].

artículo científico publicado en 2009

Lista de obras de Tanja Trarbach

A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer

A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).

Adjuvant therapy in colon cancer

Adjuvant therapy of colon carcinoma

An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer

Cancer patients and the Internet: a survey of the 'Quality of Life' Working Groups of the Arbeitsgemeinschaft für Internistische Onkologie and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS)

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

Evaluation of different protocols for gene transfer into non-obese diabetes/severe combined immunodeficiency disease mouse repopulating cells.

Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group.

Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion.

Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.

Long-term survival after "liver first" approach for locally advanced rectal cancer and synchronous liver metastases

Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy

Novel prognostic scoring system after surgery for Klatskin tumor.

Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients

Optimized retroviral transduction protocol for human progenitor cells utilizing fibronectin fragments.

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours

Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

Prognostic impact of intrahepatic lymphatic and microvascular involvement in cases of colorectal liver metastases

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction.

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial

Quality of life in pre- and postmenopausal patients with early breast cancer: a comprehensive analysis from the prospective MaLife project.

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

Rectal cancer and synchronous metastases: resection of primary tumor or not?

Safety distance in the resection of colorectal lung metastases: a prospective evaluation of satellite tumor cells with immunohistochemistry.

Surgical treatment of Klatskin tumor: liver resection versus transplantation.

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).

Survival of patients with synchronous and metachronous colorectal liver metastases--is there a difference?

Ten-year survival of esophageal cancer after an en-bloc esophagectomy.

Tumor markers as a diagnostic key for hilar Cholangiocarcinoma ⬇️

[Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology].

[Laparoscopic surgery and adjuvant therapy for colon cancer].